Magenta Therapeutics Adds $50 Million for Stem Cell Development
- Posted by Janet Tice
- On May 11, 2017
Cambridge-based Magenta Therapeutics, a biotech company developing therapies to improve and expand the use of curative stem cell transplantation, has announced completion of a $50 million Series B financing; in-licensing of a clinical-stage program from Novartis to support the use of stem cell transplantation in a variety of disease settings; and a strategic partnership with […]
Read More